Results 21 to 30 of about 1,574,312 (309)

Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011

Experimental Hematology & Oncology, 2012
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders.
Ali Natasha, Adil Salman, Shaikh Mohammad, Moosajee Munira, Masood Nehal   +4 more
doaj   +1 more source

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework

CPT: Pharmacometrics & Systems Pharmacology, 2021
The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and assess the impact of TGI metrics and baseline prognostic factors on ...
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y. Jin, René Bruno   +10 more
doaj   +1 more source

Apalutamide and Overall Survival in Prostate Cancer

European Urology, 2021
The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.We report the prespecified
Smith, Matthew R., Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris, Graff, Julie N., Olmos, David, Mainwaring, Paul N., Lee, Ji Youl, Uemura, Hiroji, De Porre, Peter, Smith, Andressa A., Brookman-May, Sabine D., Li, Susan, Zhang, Ke, Rooney, Brendan, Lopez-Gitlitz, Angela, Small, Eric J.   +17 more
openaire   +4 more sources

The Value of lncRNA HULC as a Prognostic Factor for Survival of Cancer Outcome: A Meta-Analysis

Cellular Physiology and Biochemistry, 2017
Aims: Growing evidence from recent studies has shown that lncRNA HULC plays a role in the development of multiple carcinomas. This meta-analysis aimed to analyze available data to identify the prognostic value of HULC in multiple tumors.
Xian Chen, Limin Lun, Huabin Hou, Runhua Tian, Haiping Zhang, Yunyuan Zhang   +5 more
doaj   +1 more source

Prognostic value of peripheral blood lymphocyte subsets in patients with solid cancers: a retrospective study [PDF]

Archives of the Balkan Medical Union, 2021
Introduction. Lymphocyte subsets are important in regulating immunity and specific killing of tumour cells and appear to be strongly associated with the development of solid tumours.
Marieta-Elena PANAIT, Antonela BUSCA, Ana-Maria COMAN, Mariana SAULEA, Lucica-Madalina BOLOVAN   +4 more
doaj   +1 more source

Construction and validation of a nomogram model for predicting the overall survival of colorectal cancer patients

BMC Surgery, 2023
Background Colorectal cancer (CRC) is a frequent cancer worldwide with varied survival outcomes. Objective We aimed to develop a nomogram model to predict the overall survival (OS) of CRC patients after surgery.
Guo Peiyuan, Hu xuhua, Guo Ganlin, Yin Xu, Liu Zining, Han Jiachao, Yu Bin, Wang Guiying   +7 more
doaj   +1 more source

Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey

Balkan Medical Journal, 2014
Background: Triple-negative (TN) breast cancer is a subtype of breast cancer characterised by a loss of estrogen receptor (ER), progesterone receptor (PR) expression, and the absence of human epidermal growth factor (HER2) overexpression.
Bülent Yıldız, Evren Fidan, Feyyaz Özdemir, Orhan Sezen, Halil Kavgacı, Fazıl Aydın   +5 more
doaj   +1 more source

Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Studies have shown promising survival with the use of Extended Temozolomide (E-TMZ) as compared to Conventional six cycles of Temozolomide (C-TMZ) in malignant gliomas; however, the reports are mostly limited to retrospective studies ...
Menal Bhandari, Ajeet Kumar Gandhi, Bharti Devnani, Pavnesh Kumar, Daya Nand Sharma, Pramod Kumar Julka   +5 more
doaj   +1 more source

Complete remission in metastatic hepatocellular carcinoma

JGH Open, 2023
Bone metastases from hepatocellular carcinoma (HCC) are unusual. Optimal treatment strategies are not well defined. The prognosis of this entity is very poor with a survival that does not exceed 1 year.
Wala Ben Kridis, Rim Kallel, Tahia Boudawara, Afef Khanfir   +3 more
doaj   +1 more source

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use

Trials, 2023
Background Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the ...
Vinay Prasad, Myung Sun Kim, Alyson Haslam   +2 more
doaj   +1 more source